Drug Trial Radar · NCT07532265
A Clinical Study to Evaluate the Efficacy and Safety of Frevecitinib (KN-002) in Patients With Severe Asthma
Last checked: Nov 19, 2026Latest source record: Jul 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
512
Planned (sponsor's estimate)
Start
Jul 16, 2026
Primary completion
Nov 30, 2027
Study completion Nov 30, 2027
Sponsor
- Lead sponsor
- Kinaset Therapeutics IncIndustry
- Sponsor type
- Industry
- First posted
- Apr 15, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase 2 Dose Ranging Study to Evaluate the Efficacy and Safety of Frevecitinib (KN-002) Over a 12-Week Treatment Period in Patients With Severe Asthma Not Controlled With Medium to High Dose ICS/LABA
Conditions
- Severe Asthma
Interventions
FrevecitinibDrug
Frevecitinib (KN-002) delivered via a dry powder inhaler (DPI)
PlaceboDrug
Matching placebo to frevecitinib
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pre-BD FEV1Time frame: Week 12
Locations
14 sites in 1 country. Site status is shown where the registry gives one.
Research site
Lancaster, California · Recruiting
Research site
San Jose, California · Recruiting
Research site
Brandon, Florida · Not yet recruiting
Research site
Miami, Florida · Recruiting
Research site
Tampa, Florida · Recruiting
Research site
Chicago, Illinois · Not yet recruiting
Research site
Kansas City, Missouri · Not yet recruiting
Research site
Charlotte, North Carolina · Recruiting
Research site
Pittsburgh, Pennsylvania · Not yet recruiting
Research site
Rock Hill, South Carolina · Recruiting
Research site
Dallas, Texas · Recruiting
Research site
Houston, Texas · Recruiting
Research site
San Antonio, Texas · Recruiting
Research site
Williamsburg, Virginia · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.